CPL 1001 (Sorbent Therapeutics) success in Phase II Heart Failure trial

There has been positive data from a randomized, double-blind Phase IIa clinical study of CLP 1001 from Sorbent Therapeutics. In the study of 111 Heart Failure patients with chronic kidney disease, CLP 1001 demonstrated improvement in Heart Failure symptoms as compared to placebo. CLP1001-treated patients achieved significantly greater weight loss � an accepted measurement of fluid retention � as compared to placebo over the first two weeks of treatment. This trend continued through the end of the study. After eight weeks of treatment, a greater number of patients experienced marked or moderately improved breathing in the CLP1001 group, and the average distance walked in the 6-Minute Walk Test was larger in patients receiving CLP 1001 versus the placebo population. Results were presented by Barry M. Massie, M.D., Professor, University of California, San Francisco at the Symposium at the Heart Failure Society of America meeting